logo-loader
viewPolarean Imaging PLC

Polarean Imaging on track to complete enrolment for its phase III clinical trials

Polarean Imaging PLC's (LON:POLX) chief executive Richard Hullihen talks Proactive London's Andrew Scott through the firm's 2018 results.

Polarean reported slightly higher revenues and lower costs than expected for the past calendar year.

It's currently taking its drug-and-device technology through late-stage clinical trials and he says they're on track to apply for regulatory permission in the US next year and deliver first commercial sales by end of the year.

Quick facts: Polarean Imaging PLC

Price: 20 GBX

AIM:POLX
Market: AIM
Market Cap: £22.89 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Polarean Imaging PLC named herein, including the promotion by the Company of Polarean Imaging PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Polarean Imaging eagerly awaiting readouts from its key phase III clinical...

Polarean Imaging PLC's (LON:POLX) Richard Hullihen speaks to Proactive London's Andrew Scott following the news they've now completed patient enrolment for the phase III clinical trials of its MRI lung scan technology. He says the trials are now in the image and statistical analysis stage, a...

1 month, 1 day ago

2 min read